Short-term effect of zidovudine on plasma and genital human immunodeficiency virus type 1 and viral turnover in these compartments. Mbori-Ngacha D, Richardson BA, Overbaugh J, Panteleeff DD, Nduati R, Steele M, John-Stewart G.

Citation:
MBORI- PROFNGACHADOROTHYA. "Short-term effect of zidovudine on plasma and genital human immunodeficiency virus type 1 and viral turnover in these compartments. Mbori-Ngacha D, Richardson BA, Overbaugh J, Panteleeff DD, Nduati R, Steele M, John-Stewart G.". In: J Virol. 2003 Jul;77(13):7702-5. Earthscan, London. 978-1-84407-469-3 (*); 2003.

Abstract:

The effect of zidovudine on plasma and genital human immunodeficiency virus type 1 (HIV-1) was determined in 42 antiretroviral-naive HIV-1-seropositive women in Nairobi. After 7 days of zidovudine treatment, HIV-1 RNA levels decreased by 0.5 to 1.1 log(10) in plasma and genital secretions. HIV-1 RNA half-life following zidovudine treatment was 4.7, 1.3, and 0.9 days in plasma, cervix, and vagina, respectively, and significantly shorter in genital secretions than in plasma (P < 0.001). Defining the short-term effect of zidovudine on plasma and genital HIV-1 is important for improving perinatal HIV-1 interventions.

Notes:

n/a

Website

UoN Websites Search